by Bonnie Goldberg, MA, RD, CDE

Bonnie is a Registered Dietitian with a Masters Degree in Health Education from Columbia University. She specializes in diabetes care and has spent her career educating and empowering people with diabetes. She is proud to currently work for Medtronic.

You might have heard about a new insulin pump that was recently approved by the FDA, the MiniMed® 670G system. This revolutionary new product is the world’s first hybrid closed loop insulin delivery system. This groundbreaking new technology is the first and only system that constantly self-adjusts to automatically keep your sugar levels in range, based on how you live your everyday life.

So, how does this new technology work? And how can it help you manage your diabetes better?

How Does the Hybrid Closed Loop System Work?

The MiniMed 670G system is the latest step in Medtronic’s 35-year journey toward developing a fully automated, closed loop system. With each advancement made to our SmartGuard^TM algorithm, Medtronic’s insulin pump systems enable increased automation, requiring less and less interaction with the system. For example, in the MiniMed® 630G system, which launched in August 2016, SmartGuard technology suspends insulin delivery for up to two hours when glucose levels reach a pre-set low limit, reducing exposure to low sensor glucose events. We call this feature Suspend on low.

Our latest advancement, the brand new MiniMed 670G system with SmartGuard Hybrid Closed Loop (HCL) technology, offers two new levels of personalization.

• Suspend before low: avoids lows and rebound highs proactively by automatically stopping insulin 30 minutes before you reach your pre-selected low limits, then automatically restart insulin when your levels recover, all without bothersome alerts.
• Auto mode: The Auto Mode option automatically adjusts your basal insulin delivery every 5 minutes based on your sugar levels to keep you in target range, all day and night.

In addition, the MiniMed 670G system features the Guardian® Sensor 3, Medtronic’s newest and most advanced glucose sensor. Guardian Sensor 3 is the most accurate sensor from Medtronic, now with up to 7-day wear and easy insertion. It is the FIRST and ONLY continuous glucose monitoring sensor that’s FDA approved and trusted to control insulin dosing.

Patients who participated in the clinical trial reported that the MiniMed 670G system delivered better outcomes than their previous therapy, and 80% of patients preferred the system over their regular insulin pump therapy.¹

How Can the MiniMed 670G System Help Me Manage My Diabetes Better?

What does better diabetes management look like to you? When it comes to diabetes, none of us is exactly alike. What we do, what we eat, and even how our bodies react to insulin affect our blood sugar in completely different ways. That’s why the MiniMed 670G system personalizes diabetes management with customizable options, intuitive menus, and convenient features that allow you to participate more in life.

“The MiniMed 670G system does not solve every problem a [person living with type 1 diabetes] faces, but it comes pretty darn close.”¹

For example, SmartGuard HCL technology can help stabilize sugar levels, even during exercise. You can enable a temporary sugar target and let the system adjust your basal insulin to help reduce lows during and after exercise. In addition, you can set SmartGuard HCL technology to proactively start and stop insulin when needed, helping reduce lows all night without waking you with alerts. You can awake refreshed and ready to take on the day.

As stated by a participant in the pivotal study, “I never had such good, steady, accurate readings…It’s such a smart piece of equipment; I think it would benefit practically anyone that would use it.”²

The MiniMed 670G system will be available in the spring of 2017. purchasing a MiniMed 630G system NOW is your ticket to Priority Access for the MiniMed 670G system when it becomes available in the spring of 2017. Click here for more information on how your out-of-pocket cost for the world’s first hybrid closed loop insulin delivery system could go as low as $0*.

Important Safety Information: MiniMed® 670G System

The Medtronic MiniMed 670G system is intended for continuous delivery of basal insulin (at user selectable rates) and administration of insulin boluses (in user selectable amounts) for the management of type 1 diabetes mellitus in persons, fourteen years of age and older, requiring insulin as well as for the continuous monitoring and trending of glucose levels in the fluid under the skin. The MiniMed 670G system includes SmartGuard technology, which can be programmed to automatically adjust delivery of basal insulin based on continuous glucose monitor sensor glucose values, and can suspend delivery of insulin when the sensor glucose value falls below or is predicted to fall below predefined threshold values. The system requires a prescription. The Guardian Sensor (3) glucose values are not intended to be used directly for making therapy adjustments, but rather to provide an indication of when a fingerstick may be required. A confirmatory finger stick test via the CONTOUR®NEXT LINK 2.4 blood glucose meter is required prior to making adjustments to diabetes therapy. All therapy adjustments should be based on measurements obtained using the CONTOUR®NEXT LINK 2.4 blood glucose meter and not on values provided by the Guardian Sensor (3). Always check the pump display to ensure the glucose result shown agrees with the glucose results shown on the CONTOUR®NEXT LINK 2.4 blood glucose meter. Do not calibrate your CGM device or calculate a bolus using a blood glucose meter result taken from an alternative site (palm) or from a control solution test. Do not calibrate your CGM device when sensor or blood glucose values are changing rapidly, e.g., following a meal or physical exercise. If a control solution test is out of range, please note that the result may be transmitted to your pump when in the “Always” send mode. WARNING: Medtronic performed an evaluation of the MiniMed 670G system and determined that it may not be safe for use in children under the age of 7 because of the way that the system is designed and the daily insulin requirements. Therefore this device should not be used in anyone under the age of 7 years old. This device should also not be used in patients who require less than a total daily insulin dose of 8 units per day because the device requires a minimum of 8 units per day to operate safely. Only use rapid acting U100 insulin with this system. Pump therapy is not recommended for people whose vision or hearing does not allow recognition of pump signals and alarms. Pump therapy is not recommended for people who are unwilling or unable to maintain contact with their healthcare professional. The safety of the MiniMed 670G system has not been studied in pregnant women. For complete details, including product and important safety information concerning the system and its components, please consult http://www.medtronicdiabetes.com/important-safety-information#minimed-670g and the appropriate user guide at http://www.medtronicdiabetes.com/download-library.

MiniMed is a registered trademark and SmartGuard is a trademark of Medtronic, MiniMed Inc.

Ascensia, the Ascensia Diabetes Care logo and Contour are trademarks and/or registered trademarks of Ascensia Diabetes Care.

1.       Continued Access Study patient focus group. Data on file.

2.       MiniMed 670G pivotal study participant. Data on file.

*Offer available until April 28, 2017.